摘要
目的比较布地奈德混悬液(普米克令舒)和静脉用甲基强的松龙在治疗慢性阻塞性肺疾患(COPD)急性加重期的疗效和安全性。方法共人选96例 COPD 急性加重期住院患者,随机分组接受以下治疗:48例患者接受普米克令舒4 mg 雾化吸入,每天2次,共10 d;48例患者接受静脉滴注甲基强的松龙40 mg,每天3次共3 d天,后改为每天1次共7 d。分别于治疗前、治疗后2 h、第3天、第10天进行呼吸困难评分;治疗前,治疗后第3天、第10天分别测定 FEV_1%、PEF、PaO_2、PaCO_2。结果两组患者治疗后呼吸困难评分均较治疗前改善(P<0.01或 P<0.05);治疗后2 h 两组间呼吸困难评分有明显差异(P<0.05),而治疗后第3天、第10天两组间无明显差异。治疗后 FEV_1%、PEF、PaO_2与治疗前有明显差异(P<0.01或 P<0.05).而 PaCO_2无明显差别;两组间治疗后各指标无差异。普米克令舒组不良反应发生率明显低于甲强龙治疗组(P<0.01)。结论普米克令舒可替代静脉用甲基强的松龙治疗 COPD 急性加重期患者。
Objective Comparing the efficacy and safety on treating acute exacerbation phase of COPD between budesonide suspl （pulmicort respules）and intravenous drip of methylprednisolone. Methods We choose 96 cases of acute exacerbation phase of COPD patients, the patients treated with the following therapies at random： 48 cases adopt pulmicort respules 4 mg twice a day for 10 days ,4g cases adopt 40 mg methylprednisolone by intravenous drip, twice a day for 3 days, then 40 mg once a day tolally for 7 days 2 hours ,3 days and 10 days before therapy and after treatment,we evaluated dyspnea ranking and also detemined the PEF, FEV1%, PaO2, PaCO2 pretherapy,3 days, 10 days after treatment. Results After therapy, the dyspnea ranking of two groups all improved （ P 〈 0. 01 or P 〈 0. 05 ） and it is obvious difference between two groups 2 h after treatment. （ P 〈 0. 05 ）, but no obvious difference 3 d, 10 d after treatment. The PEF, FEV1%, PaO2 of two groups showed great difference as pretherapy（ P 〈 0.01 or P 〈0. 05 ） but PaCO2 showed no difference ,it is no obvious difference of PEF, FEV1%, PaO2, PaCO2 between two groups after treatment. The adverse effects incidence rate in pulmicort group was obviously lower than methylprenidsolone group（ P 〈0. 01 ） Conclusion The research showed pulmieort respules could replace the methylprednisolone for the therapy of COPD acute exacerbation.
出处
《临床急诊杂志》
CAS
2007年第4期200-202,共3页
Journal of Clinical Emergency
